Unlabeled uses of botulinum toxins: A review, part 2

American Journal of Health-System Pharmacy

Volumn 63, Issue 3, 2006, Pages 225-232

  Cheng, Christine M ^a   Chen, Jennifer S ^b   Patel, Rosalie P ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Box 0622 ^*

Author keywords

Botulinum toxin A; Botulinum toxins; Drugs; Mechanism of action; Skeletal muscle relaxants; Toxicity

Indexed keywords

ACETYLCHOLINE; ADRENALIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BACLOFEN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DANTROLENE; DIAZEPAM; GLYCERYL TRINITRATE; MUSCLE RELAXANT AGENT; PLACEBO; SPASMOLYTIC AGENT;

ACETYLCHOLINE RELEASE; ANAPHYLAXIS; ANUS FISSURE; ANUS SPHINCTER; BLEPHAROSPASM; BURNING SENSATION; CEREBRAL PALSY; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DAILY LIFE ACTIVITY; DROWSINESS; DRUG EFFICACY; DRUG INDICATION; DRUG LABELING; DRUG SAFETY; DRUG TOLERANCE; DYSTONIA; ECCHYMOSIS; ELECTROSTIMULATION; ESOPHAGUS ACHALASIA; ESSENTIAL TREMOR; FALLING; FECES INCONTINENCE; FOOD AND DRUG ADMINISTRATION; GAIT; HAND PALM; HEADACHE; HUMAN; HYPERHIDROSIS; HYPOTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MIGRAINE; MUSCLE WEAKNESS; NEUROMUSCULAR SYNAPSE; PAIN; PES EQUINUS; PHYSIOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SKELETAL MUSCLE; SMOOTH MUSCLE; SPASTICITY; STROKE; TACHYPHYLAXIS; TREATMENT OUTCOME; ULCER HEALING; WEAKNESS;

EID: 31544443857     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/sp/06001     Document Type: Review

References (34)

1. Gorfine SR. Topical nitroglycerin therapy for anal fissures and ulcers. N Engl J Med. 1995; 333:1156-7.
2. Nelson R. Nonsurgical therapy for anal fissure. The Cochrane database of systematic reviews 2003. Issue 4. Chichester, United Kingdom: John Wiley; 2005.
3. Maria G, Cassetta E, Gui D et al. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med. 1998; 338:217-20.
4. Siproudhis L, Sebille V, Pigot F et al. Lack of efficacy of botulinum toxin in chronic anal fissure. Aliment Pharmacol Ther. 2003; 18:515-24.
5. Brisinda G, Maria G, Bentivoglio AR et al. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med. 1999; 341:65-9.
6. [Erratum, N Engl J Med. 1999; 341:624.]
7. Mentes BB, Irkorucu O, Akin M et al. Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. Dis Colon Rectum. 2003; 46:232-7.
8. Arroyo A, Perez F, Serrano P et al. Surgical versus chemical (botulinum toxin) sphincterotomy for chronic anal fissure: long-term results of a prospective randomized clinical and manometric study. Am J Surg. 2005; 189:429-34.
9. Giral A, Memisoglu K, Gultekin Y et al. Botulinum toxin injection versus lateral internal sphincterotomy in the treatment of chronic anal fissure: a non-randomized controlled trial. BMC Gastroenterol. 2004; 4:7.
10. Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs. 2003; 5:11-23.
11. Warner WC. Cerebral palsy. In: Canale ST, ed. Campbell's operative orthopaedics. 10th ed. Carlsbad, CA: Mosby, Inc.; 2003:1214-6.
12. Koman LA, Mooney JF 3rd, Smith BP et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop. 2000; 20:108-15.
13. Koman LA, Mooney JF 3rd, Smith BP et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop. 1994; 14:299-303.
14. Sutherland DH, Kaufman KR, Wyatt MP et al. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture. 1999; 10:1-9.
15. Baker R, Jasinski M, Maciag-Tymecka I et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol. 2002; 44:666-75.
16. Reddihough DS, King JA, Coleman GJ et al. Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Dev Med Child Neurol. 2002; 44:820-7.
17. Ubhi T, Bhakta BB, Ives HL et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child. 2000; 83:481-7.
18. Flett PJ, Stern LM, Waddy H et al. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health. 1999; 35:71-7.
19. Corry IS, Cosgrove AP, Duffy CM et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop. 1998; 18:304-11.
20. Kay RM, Rethlefsen SA, Fern-Buneo A et al. Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy. J Bone Joint Surg Am. 2004; 86:2377-84.
21. Corry IS, Cosgrove AP, Walsh EG et al. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol. 1997; 39:185-93.
22. Childers MK, Brashear A, Jozefczyk P et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004; 85:1063-9.
23. Brashear A, Gordon MF, Elovic E et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002; 347:395-400.
24. Simpson DM, Alexander DN, O'Brien CF et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996; 46:1306-10.
25. Bakheit AM, Pittock S, Moore AP et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001; 8:559-65.
26. Smith SJ, Ellis E, White S et al. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil. 2000; 14:5-13.
27. Bakheit AM, Thilmann AF, Ward AB et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000; 31:2402-6.
28. Hesse S, Reiter F, Konrad M et al. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil. 1998; 12:381-8.
29. Brashear A, McAfee AL, Kuhn ER et al. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo controlled trial. Arch Phys Med Rehabil. 2004; 85:705-9.
30. Pittock SJ, Moore AP, Hardiman O et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003; 15:289-300.
31. Richardson D, Sheean G, Werring D et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry. 2000; 69:499-506.
32. Kirazli Y, On AY, Kismali B et al. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil. 1998; 77:510-5.
33. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004; 20:981-90.
34. Lew MF, Adornato BT, Duane DD et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997; 49:701-7.